Curaxin quinacrine: Phase I data

A dose-escalation Phase I trial in 32 patients with advanced breast, gastric, hepatic, pancreatic and colorectal cancer showed that once-daily oral CBL0102 was generally well tolerated with skin discoloration, gastrointestinal disorders and hepatic transaminase elevations reported as the most common adverse events. The recommended Phase II dose is once-daily 400 mg CBL0102. At week 8, there was a partial tumor regression in 1 breast cancer patient who had a 46% reduction in target lesion maximum dimensions. There were 4 cases of stable disease in hepatocellular carcinoma (HCC), breast, salivary gland and rectal cancer patients. ...